Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study
Authors not listed
Vienna Institute for Research in Ocular Surgery · 2024
Abstract
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2024). Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study. <em>Vienna Institute for Research in Ocular Surgery</em>. https://clinicaltrials.gov/study/NCT07390253
Vancouver
Anonymous. Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study. Vienna Institute for Research in Ocular Surgery. 2024.
BibTeX
@misc{anon2024Aflibe,
title = {Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study},
author = {Anonymous},
journal = {Vienna Institute for Research in Ocular Surgery},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Bayer 2016
Open access · US-GOV
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
IRCCS San Raffaele 2011
Open access · US-GOV
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Survey of Ophthalmology 1988
Open access · CC-BY
Age-related macular degeneration
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Vastra Gotaland Region 2020
Open access · US-GOV
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
pico-tesla Magnetic Therapies, LLC 2010
Open access · US-GOV